Support for Clinical Research in Regenerative Medicine and Cell Therapy Using Umbilical Cord Blood

「For cord blood, existing clinical studies on cerebral palsy, ASD and other conditions will continue to be promoted.」

「As clinical research in regenerative medicine, clinical research on "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder (ASD)," being conducted jointly with the Department of Developmental Pediatrics at the Osaka Metropolitan University Graduate School of Medicine, has begun, and cord blood has been administered to multiple patients.」

「The clinical study being conducted jointly with the Department of Developmental Pediatrics, Graduate School of Medicine, Osaka Metropolitan University, on the “Development of a Treatment Using Autologous Umbilical Cord Blood Nucleated Cells for Autism Spectrum Disorder (ASD)” has begun, and umbilical cord blood has been administered to multiple patients.」

「The clinical study received many applications to participate, exceeding the recruitment capacity, and administration has already been performed in the first case. In the cord blood administration program for children with cerebral palsy and other conditions being conducted by Duke University in the United States with FDA authorization, participation by people whose cord blood is stored by the company is increasing, and the program has become established as a pathway to treatment using cord blood.」

「For the Phase II clinical study to further evaluate efficacy, the implementation plan was deemed appropriate by the Osaka University First Accredited Committee for Regenerative Medicine in February 2024. As of March 2025, consideration is under way to conduct the study as Advanced Medicine B. In January 2025, the summary report for this clinical study was reviewed by the Accredited Committee for Regenerative Medicine and deemed acceptable, and a paper is expected to be published in the future.」

「Clinical research on "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder," announced last June with the Department of Developmental Pediatrics at the Osaka Metropolitan University Graduate School of Medicine, has begun, and the company issued a press release on 29 October. Recruitment of participants (subjects) is scheduled to begin. Autism spectrum disorder (ASD) is said to be diagnosed in 1 in 100 people, and the company believes that the start of this clinical research will further enhance the value of storage.」

「In the United States, the number of cases involving people whose cord blood is stored by the company participating in Duke University's FDA-authorized cord blood administration program for children with cerebral palsy and other conditions is increasing, and the results have also been favorable. The company also announced in June last year that it had decided, together with the group, to begin "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder," and is preparing to begin clinical research in 2024.」

「The company announced in June this year that it had decided, together with the group, to begin "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder," and is preparing to begin clinical research in 2024.」

「The company announced in June this year that it had decided, together with the group, to begin "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder."」

「As of 31 March 2023, subjects corresponding to the planned number of cases, 5, had received treatment, and the study was progressing smoothly.」

「In the United States, following favorable results from Duke University's Phase II trial, the university's cord blood administration program for children with cerebral palsy and other conditions is progressing, and the number of cases involving people whose cord blood is stored by the company is increasing.」

「In regenerative medicine using cord blood, Kochi University Hospital's Department of Pediatrics published favorable results this August from Japan's first clinical study, a Phase I trial of autologous cord blood administration for children with cerebral palsy. A multicenter clinical study led by the Department of Developmental Pediatrics at the Osaka Metropolitan University Graduate School of Medicine is also progressing for autologous cord blood stem cell administration in children with hypoxic-ischemic encephalopathy (HIE), with administration to the first subject successfully completed.」

「In the United States, following favorable results from Duke University's Phase II clinical study, a program to treat cerebral palsy and other conditions using cord blood is being conducted at the university. A pathway has also been established for people whose cord blood is stored by the company to travel from Japan to the United States for treatment, representing significant progress.」

「As of 31 March 2022, multiple subjects had received treatment, and the study was progressing smoothly.」

「In the United States, following results from a Phase II clinical study at Duke University, plans were made to launch a specialist clinic providing treatment for cerebral palsy and other conditions using cord blood, representing significant progress.」

「In research and development in regenerative medicine, clinical research using cord blood for pediatric neurological diseases is steadily progressing at Kochi University Hospital, Osaka City University Hospital and other institutions.」

「The company will expand users of its cell banking business by supporting medical institutions working on regenerative medicine and cell therapy for central nervous system diseases, including hypoxic-ischemic encephalopathy, cerebral palsy and autism spectrum disorder, using cord blood, so that their clinical research can progress smoothly.」